These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 17875776)

  • 1. Fas ligand delivery by a prostate-restricted replicative adenovirus enhances safety and antitumor efficacy.
    Li X; Liu YH; Zhang YP; Zhang S; Pu X; Gardner TA; Jeng MH; Kao C
    Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5463-73. PubMed ID: 17875776
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene therapy for prostate cancer by controlling adenovirus E1a and E4 gene expression with PSES enhancer.
    Li X; Zhang YP; Kim HS; Bae KH; Stantz KM; Lee SJ; Jung C; Jiménez JA; Gardner TA; Jeng MH; Kao C
    Cancer Res; 2005 Mar; 65(5):1941-51. PubMed ID: 15753394
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumor activity of Ad-IU2, a prostate-specific replication-competent adenovirus encoding the apoptosis inducer, TRAIL.
    Jiménez JA; Li X; Zhang YP; Bae KH; Mohammadi Y; Pandya P; Kao C; Gardner TA
    Cancer Gene Ther; 2010 Mar; 17(3):180-91. PubMed ID: 19798123
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate-restricted replicative adenovirus expressing human endostatin-angiostatin fusion gene exhibiting dramatic antitumor efficacy.
    Li X; Liu YH; Lee SJ; Gardner TA; Jeng MH; Kao C
    Clin Cancer Res; 2008 Jan; 14(1):291-9. PubMed ID: 18172281
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A complex adenovirus vector that delivers FASL-GFP with combined prostate-specific and tetracycline-regulated expression.
    Rubinchik S; Wang D; Yu H; Fan F; Luo M; Norris JS; Dong JY
    Mol Ther; 2001 Nov; 4(5):416-26. PubMed ID: 11708878
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Docetaxel increases antitumor efficacy of oncolytic prostate-restricted replicative adenovirus by enhancing cell killing and virus distribution.
    Li X; Liu Y; Tang Y; Roger P; Jeng MH; Kao C
    J Gene Med; 2010 Jun; 12(6):516-27. PubMed ID: 20527044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting prostate cancer with conditionally replicative adenovirus using PSMA enhancer.
    Lee SJ; Zhang Y; Lee SD; Jung C; Li X; Kim HS; Bae KH; Jeng MH; Kao C; Gardner T
    Mol Ther; 2004 Dec; 10(6):1051-8. PubMed ID: 15564137
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel bystander effect involving tumor cell-derived Fas and FasL interactions following Ad.HSV-tk and Ad.mIL-12 gene therapies in experimental prostate cancer.
    Hall SJ; Canfield SE; Yan Y; Hassen W; Selleck WA; Chen SH
    Gene Ther; 2002 Apr; 9(8):511-7. PubMed ID: 11948376
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A conditional replication-competent adenoviral vector, Ad-OC-E1a, to cotarget prostate cancer and bone stroma in an experimental model of androgen-independent prostate cancer bone metastasis.
    Matsubara S; Wada Y; Gardner TA; Egawa M; Park MS; Hsieh CL; Zhau HE; Kao C; Kamidono S; Gillenwater JY; Chung LW
    Cancer Res; 2001 Aug; 61(16):6012-9. PubMed ID: 11507044
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel prostate-specific promoter derived from PSA and PSMA enhancers.
    Lee SJ; Kim HS; Yu R; Lee K; Gardner TA; Jung C; Jeng MH; Yeung F; Cheng L; Kao C
    Mol Ther; 2002 Sep; 6(3):415-21. PubMed ID: 12231179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination therapy of androgen-independent prostate cancer using a prostate restricted replicative adenovirus and a replication-defective adenovirus encoding human endostatin-angiostatin fusion gene.
    Li X; Raikwar SP; Liu YH; Lee SJ; Zhang YP; Zhang S; Cheng L; Lee SD; Juliar BE; Gardner TA; Jeng MH; Kao C
    Mol Cancer Ther; 2006 Mar; 5(3):676-84. PubMed ID: 16546982
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models.
    Denmeade SR; Sokoll LJ; Dalrymple S; Rosen DM; Gady AM; Bruzek D; Ricklis RM; Isaacs JT
    Prostate; 2003 Mar; 54(4):249-57. PubMed ID: 12539223
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ad5/35E1aPSESE4: A novel approach to marking circulating prostate tumor cells with a replication competent adenovirus controlled by PSA/PSMA transcription regulatory elements.
    Hwang JE; Joung JY; Shin SP; Choi MK; Kim JE; Kim YH; Park WS; Lee SJ; Lee KH
    Cancer Lett; 2016 Mar; 372(1):57-64. PubMed ID: 26723876
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate-specific expression of the diphtheria toxin A chain (DT-A): studies of inducibility and specificity of expression of prostate-specific antigen promoter-driven DT-A adenoviral-mediated gene transfer.
    Li Y; McCadden J; Ferrer F; Kruszewski M; Carducci M; Simons J; Rodriguez R
    Cancer Res; 2002 May; 62(9):2576-82. PubMed ID: 11980652
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lovastatin enhances adenovirus-mediated TRAIL induced apoptosis by depleting cholesterol of lipid rafts and affecting CAR and death receptor expression of prostate cancer cells.
    Liu Y; Chen L; Gong Z; Shen L; Kao C; Hock JM; Sun L; Li X
    Oncotarget; 2015 Feb; 6(5):3055-70. PubMed ID: 25605010
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Conditionally replicative adenovirus driven by the human telomerase promoter provides broad-spectrum antitumor activity without liver toxicity.
    Irving J; Wang Z; Powell S; O'Sullivan C; Mok M; Murphy B; Cardoza L; Lebkowski JS; Majumdar AS
    Cancer Gene Ther; 2004 Mar; 11(3):174-85. PubMed ID: 14726958
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficient melanoma cell killing and reduced melanoma growth in mice by a selective replicating adenovirus armed with tumor necrosis factor-related apoptosis-inducing ligand.
    Fecker LF; Rückert S; Kurbanov BM; Schmude M; Stockfleth E; Fechner H; Eberle J
    Hum Gene Ther; 2011 Apr; 22(4):405-17. PubMed ID: 20977303
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantification and characterization of the bystander effect in prostate cancer cells following adenovirus-mediated FasL expression.
    Hyer ML; Sudarshan S; Schwartz DA; Hannun Y; Dong JY; Norris JS
    Cancer Gene Ther; 2003 Apr; 10(4):330-9. PubMed ID: 12679806
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oncolytic adenovirus CG7870 in combination with radiation demonstrates synergistic enhancements of antitumor efficacy without loss of specificity.
    Dilley J; Reddy S; Ko D; Nguyen N; Rojas G; Working P; Yu DC
    Cancer Gene Ther; 2005 Aug; 12(8):715-22. PubMed ID: 15832172
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate specific membrane antigen (PSMA) is a tissue-specific target for adenoviral transduction of prostate cancer in vitro.
    Kraaij R; van Rijswijk AL; Oomen MH; Haisma HJ; Bangma CH
    Prostate; 2005 Feb; 62(3):253-9. PubMed ID: 15389777
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.